๐ก Whatโs in this blog?
- What are Azacitidine and Decitabine?
- How they work in treating Myelodysplastic Syndromes (MDS)
- Key similarities and differences
- Effectiveness and side effects
- Top brands available in India
- How to buy Azacitidine and Decitabine in bulk or single packs
- Why Unnati Pharmax is a trusted global oncology supplier
๐งฌ Introduction
For patients diagnosed with Myelodysplastic Syndrome (MDS), treatment often begins with two cornerstone drugs โ Azacitidine and Decitabine. These medicines are hypomethylating agents (HMAs) that help improve bone marrow function and slow disease progression.
Both drugs work to restore normal blood cell production, improve quality of life, and, in many cases, delay the transformation of MDS into acute myeloid leukemia (AML).
But how do they differ? Which one is more effective? And how can hospitals, clinics, and pharmacies source them safely and affordably?
Letโs explore each in depth.
โ๏ธ What is Azacitidine?
Azacitidine (brand names: Vidaza, Azadine, Azacit, Cytodine) is a pyrimidine nucleoside analog that gets incorporated into DNA and RNA, helping reprogram abnormal bone marrow cells.
Mechanism of Action:
Azacitidine inhibits DNA methyltransferase, reducing abnormal methylation and allowing genes responsible for normal cell growth to reactivate. This leads to healthier blood formation.
Approved Uses:
- Myelodysplastic Syndromes (MDS)
- Acute Myeloid Leukemia (AML)
- Chronic Myelomonocytic Leukemia (CMML)
Dosage:
Typical starting dose: 75 mg/mยฒ daily for 7 days, repeated every 28 days.
It can be administered subcutaneously or intravenously.
โ๏ธ What is Decitabine?
Decitabine (brand names: Dacogen, Decitax, Decitas, Decitabine Natco) is another DNA methyltransferase inhibitor with a similar mechanism to Azacitidine โ but slightly different pharmacokinetics.
Mechanism of Action:
Decitabine integrates directly into DNA (not RNA like Azacitidine) and triggers DNA hypomethylation, which promotes normal differentiation and growth of bone marrow cells.
Approved Uses:
- Myelodysplastic Syndromes (MDS)
- Acute Myeloid Leukemia (AML)
- Investigational use in chronic leukemias and solid tumors
Dosage:
Typical regimen: 20 mg/mยฒ IV for 5 days every 4 weeks.
Treatment cycles continue until disease progression or unacceptable toxicity.
โ๏ธ Azacitidine vs. Decitabine: A Detailed Comparison
| Parameter | Azacitidine | Decitabine |
|---|---|---|
| Drug Class | DNA methylation inhibitor | DNA methylation inhibitor |
| Mechanism | Acts on both DNA and RNA | Acts only on DNA |
| Route | Subcutaneous or IV | Intravenous only |
| Cycle Duration | 7-day treatment every 28 days | 5-day treatment every 28 days |
| Main Indication | MDS, AML, CMML | MDS, AML |
| Response Rate | 50โ60% | 40โ50% |
| Overall Survival (OS) | Slightly longer | Slightly faster initial response |
| Convenience | Flexible dosing routes | Easier administration for hospitals |
| Common Side Effects | Nausea, fatigue, low platelets | Neutropenia, anemia, infections |
Both drugs are considered equally effective, with treatment choice often based on patient tolerance, dosing schedule, and hospital protocol.
๐ Common Side Effects
Azacitidine:
- Nausea and vomiting
- Injection site redness
- Fatigue
- Low blood counts (neutropenia, thrombocytopenia)
Decitabine:
- Fever and infections due to low white cells
- Fatigue
- Nausea
- Bleeding tendency
Supportive care with antibiotics, blood transfusions, and growth factors is often used during treatment.
๐ Popular Brands in India
| Medicine | Brand Name | Manufacturer | Form |
|---|---|---|---|
| Azacitidine | Azadine | Intas Pharma | Injection (100 mg) |
| Vidaza | Celgene | Injection (100 mg) | |
| Azacit | Natco Pharma | Injection (100 mg) | |
| Decitabine | Dacogen | Janssen | Injection (50 mg) |
| Decitax | Dr. Reddyโs | Injection (50 mg) | |
| Decitas | Natco Pharma | Injection (50 mg) |
All of these formulations are available with Unnati Pharmax for bulk supply and retail distribution.
๐ฅ How to Choose Between Azacitidine and Decitabine
| If You Need | Go For |
|---|---|
| Easier injection option (IV or SC) | Azacitidine |
| Shorter cycle (5 days) | Decitabine |
| Slightly better long-term survival | Azacitidine |
| Faster initial hematologic improvement | Decitabine |
| Patient preference for home injection | Azacitidine |
Your doctor will choose based on your blood counts, performance status, and prior treatments.
๐งพ How to Buy Azacitidine or Decitabine (Bulk & Retail)
You can order Azacitidine and Decitabine through Unnati Pharmax, Indiaโs trusted oncology exporter.
We supply:
- ๐ 100% original and WHO-GMP-certified oncology injectables
- ๐ Global export support (Asia, Africa, Europe, Middle East)
- ๐ข Bulk supply to hospitals, tender distributors, and pharmacies
- ๐ฉโโ๏ธ Single vials for patient-specific use
๐ Buy now or request a bulk quote:
๐ www.unnatipharmax.com
๐ง info@unnatipharmax.com
๐ Why Choose Unnati Pharmax?
At Unnati Pharmax, we specialize in the export and supply of oncology, antiviral, nephrology, and immunosuppressant medicines.
Our benefits:
- Licensed pharmaceutical exporter (India)
- Competitive wholesale pricing
- Cold-chain shipment with full regulatory documentation
- 24/7 support for bulk orders and tenders
We ensure timely global delivery of quality-assured oncology medicines.
๐ External References
- NIH โ Azacitidine Drug Summary
- Cancer Research UK โ Decitabine Overview
- FDA Label โ Azacitidine & Decitabine
๐งญ Conclusion
Both Azacitidine and Decitabine are revolutionary drugs in the treatment of MDS and AML. While they share similar mechanisms, their differences in dosing and administration make each suitable for specific patient types.
Whether you are a hospital, distributor, or individual patient, sourcing authentic, affordable, and regulatory-approved oncology medicines is critical โ and Unnati Pharmax is your trusted partner for that.
๐ Related Blogs
- Treatment of Myelodysplastic Syndrome: Latest Therapies & Drugs
- Lenalidomide Uses: Everything You Should Know About This Immunomodulatory Drug
- Top Oncology Medicines for Export from India โ 2025 Edition
- Understanding Luspatercept: A New Hope for MDS Patients with Anemia
- Stem Cell Transplant in Blood Disorders: Step-by-Step Overview

Add comment